Skip to main content
NASDAQ:RPHM

Reneo Pharmaceuticals Competitors

$8.20
+0.19 (+2.37 %)
(As of 05/14/2021 01:29 PM ET)
Add
Compare
Today's Range
$8.02
$8.80
50-Day Range N/A
52-Week Range
$7.87
$17.18
Volume1,163 shs
Average Volume94,321 shs
Market Capitalization$198.53 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Reneo Pharmaceuticals (NASDAQ:RPHM) Vs. PHAR, VOR, PHVS, FDMT, BOLT, and GRCL

Should you be buying RPHM stock or one of its competitors? Companies in the industry of "biotechnology" are considered alternatives and competitors to Reneo Pharmaceuticals, including Pharming Group (PHAR), Vor Biopharma (VOR), Pharvaris B.V. (PHVS), 4D Molecular Therapeutics (FDMT), Bolt Biotherapeutics (BOLT), and Gracell Biotechnologies (GRCL).

Reneo Pharmaceuticals (NASDAQ:RPHM) and Pharming Group (NASDAQ:PHAR) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, profitability, earnings, institutional ownership, risk and analyst recommendations.

Profitability

This table compares Reneo Pharmaceuticals and Pharming Group's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Reneo PharmaceuticalsN/AN/AN/A
Pharming GroupN/AN/AN/A

Valuation & Earnings

This table compares Reneo Pharmaceuticals and Pharming Group's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Reneo PharmaceuticalsN/AN/AN/AN/AN/A
Pharming GroupN/AN/AN/AN/AN/A

Analyst Ratings

This is a summary of current ratings and target prices for Reneo Pharmaceuticals and Pharming Group, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Reneo Pharmaceuticals00303.00
Pharming Group0000N/A

Reneo Pharmaceuticals presently has a consensus price target of $31.3333, indicating a potential upside of 287.79%. Given Reneo Pharmaceuticals' higher probable upside, research analysts plainly believe Reneo Pharmaceuticals is more favorable than Pharming Group.

Summary

Reneo Pharmaceuticals beats Pharming Group on 2 of the 2 factors compared between the two stocks.

Reneo Pharmaceuticals (NASDAQ:RPHM) and Vor Biopharma (NYSE:VOR) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, dividends, risk, earnings and valuation.

Valuation & Earnings

This table compares Reneo Pharmaceuticals and Vor Biopharma's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Reneo PharmaceuticalsN/AN/AN/AN/AN/A
Vor BiopharmaN/AN/AN/AN/AN/A

Profitability

This table compares Reneo Pharmaceuticals and Vor Biopharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Reneo PharmaceuticalsN/AN/AN/A
Vor BiopharmaN/AN/AN/A

Analyst Ratings

This is a summary of recent recommendations and price targets for Reneo Pharmaceuticals and Vor Biopharma, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Reneo Pharmaceuticals00303.00
Vor Biopharma10402.60

Reneo Pharmaceuticals presently has a consensus target price of $31.3333, suggesting a potential upside of 287.79%. Vor Biopharma has a consensus target price of $48.20, suggesting a potential upside of 151.83%. Given Reneo Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts clearly believe Reneo Pharmaceuticals is more favorable than Vor Biopharma.

Summary

Reneo Pharmaceuticals beats Vor Biopharma on 2 of the 3 factors compared between the two stocks.

Pharvaris B.V. (NASDAQ:PHVS) and Reneo Pharmaceuticals (NASDAQ:RPHM) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, earnings, dividends, risk, valuation, institutional ownership and analyst recommendations.

Profitability

This table compares Pharvaris B.V. and Reneo Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Pharvaris B.V.N/AN/AN/A
Reneo PharmaceuticalsN/AN/AN/A

Valuation and Earnings

This table compares Pharvaris B.V. and Reneo Pharmaceuticals' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Pharvaris B.V.N/AN/AN/AN/AN/A
Reneo PharmaceuticalsN/AN/AN/AN/AN/A

Analyst Recommendations

This is a breakdown of current ratings and price targets for Pharvaris B.V. and Reneo Pharmaceuticals, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Pharvaris B.V.01302.75
Reneo Pharmaceuticals00303.00

Pharvaris B.V. presently has a consensus price target of $47.50, indicating a potential upside of 113.48%. Reneo Pharmaceuticals has a consensus price target of $31.3333, indicating a potential upside of 287.79%. Given Reneo Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Reneo Pharmaceuticals is more favorable than Pharvaris B.V..

Summary

Reneo Pharmaceuticals beats Pharvaris B.V. on 2 of the 2 factors compared between the two stocks.

Reneo Pharmaceuticals (NASDAQ:RPHM) and 4D Molecular Therapeutics (NASDAQ:FDMT) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, analyst recommendations, earnings, valuation, institutional ownership, dividends and profitability.

Valuation and Earnings

This table compares Reneo Pharmaceuticals and 4D Molecular Therapeutics' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Reneo PharmaceuticalsN/AN/AN/AN/AN/A
4D Molecular TherapeuticsN/AN/AN/AN/AN/A

Analyst Ratings

This is a summary of recent recommendations for Reneo Pharmaceuticals and 4D Molecular Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Reneo Pharmaceuticals00303.00
4D Molecular Therapeutics01202.67

Reneo Pharmaceuticals currently has a consensus target price of $31.3333, suggesting a potential upside of 287.79%. 4D Molecular Therapeutics has a consensus target price of $45.50, suggesting a potential upside of 69.46%. Given Reneo Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts clearly believe Reneo Pharmaceuticals is more favorable than 4D Molecular Therapeutics.

Profitability

This table compares Reneo Pharmaceuticals and 4D Molecular Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Reneo PharmaceuticalsN/AN/AN/A
4D Molecular TherapeuticsN/AN/AN/A

Summary

Reneo Pharmaceuticals beats 4D Molecular Therapeutics on 3 of the 3 factors compared between the two stocks.

Bolt Biotherapeutics (NASDAQ:BOLT) and Reneo Pharmaceuticals (NASDAQ:RPHM) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, institutional ownership, dividends, valuation, analyst recommendations, earnings and risk.

Profitability

This table compares Bolt Biotherapeutics and Reneo Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Bolt BiotherapeuticsN/AN/AN/A
Reneo PharmaceuticalsN/AN/AN/A

Earnings and Valuation

This table compares Bolt Biotherapeutics and Reneo Pharmaceuticals' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bolt BiotherapeuticsN/AN/AN/AN/AN/A
Reneo PharmaceuticalsN/AN/AN/AN/AN/A

Analyst Recommendations

This is a summary of recent ratings and target prices for Bolt Biotherapeutics and Reneo Pharmaceuticals, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Bolt Biotherapeutics00403.00
Reneo Pharmaceuticals00303.00

Bolt Biotherapeutics presently has a consensus price target of $41.00, suggesting a potential upside of 124.66%. Reneo Pharmaceuticals has a consensus price target of $31.3333, suggesting a potential upside of 287.79%. Given Reneo Pharmaceuticals' higher possible upside, analysts clearly believe Reneo Pharmaceuticals is more favorable than Bolt Biotherapeutics.

Gracell Biotechnologies (NASDAQ:GRCL) and Reneo Pharmaceuticals (NASDAQ:RPHM) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, institutional ownership, valuation, profitability, earnings, analyst recommendations and dividends.

Profitability

This table compares Gracell Biotechnologies and Reneo Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Gracell BiotechnologiesN/AN/AN/A
Reneo PharmaceuticalsN/AN/AN/A

Analyst Recommendations

This is a summary of current ratings and price targets for Gracell Biotechnologies and Reneo Pharmaceuticals, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Gracell Biotechnologies00403.00
Reneo Pharmaceuticals00303.00

Gracell Biotechnologies presently has a consensus target price of $34.50, suggesting a potential upside of 233.98%. Reneo Pharmaceuticals has a consensus target price of $31.3333, suggesting a potential upside of 287.79%. Given Reneo Pharmaceuticals' higher probable upside, analysts clearly believe Reneo Pharmaceuticals is more favorable than Gracell Biotechnologies.

Valuation and Earnings

This table compares Gracell Biotechnologies and Reneo Pharmaceuticals' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Gracell BiotechnologiesN/AN/AN/AN/AN/A
Reneo PharmaceuticalsN/AN/AN/AN/AN/A

Ad MicroSmallCap
Psychedelic Stock Goes Nuts as FDA Approval Inches Closer
Big league investors investing in mind-blowing psychedelic stocks in a big way.

Reneo Pharmaceuticals Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Pharming Group logo
PHAR
Pharming Group
0.0$11.91+9.2%$763.78 millionN/A0.00News Coverage
Gap Down
Vor Biopharma logo
VOR
Vor Biopharma
1.5$19.14+2.9%$731.50 millionN/A0.00Analyst Upgrade
Gap Up
Pharvaris B.V. logo
PHVS
Pharvaris B.V.
1.5$22.25+0.0%$708.44 millionN/A0.00Gap Up
FDMT
4D Molecular Therapeutics
1.3$26.80+1.4%$705.26 millionN/A0.00Earnings Announcement
News Coverage
Bolt Biotherapeutics logo
BOLT
Bolt Biotherapeutics
1.3$18.25+0.4%$665.89 millionN/A0.00Gap Down
Gracell Biotechnologies logo
GRCL
Gracell Biotechnologies
1.4$10.40+6.3%$655.33 millionN/A0.00News Coverage
Gap Up
FNCH
Finch Therapeutics Group
2.0$12.09+0.5%$567.15 millionN/A0.00
Inventiva logo
IVA
Inventiva
1.4$14.15+1.1%$546.61 millionN/A0.00
VACC
Vaccitech
0.3$16.97+7.2%$536.51 millionN/A0.00News Coverage
Gap Up
ACHL
Achilles Therapeutics
1.6$13.65+7.6%$512.24 millionN/A0.00Earnings Announcement
Quiet Period Expiration
Analyst Revision
Gap Up
MIGI
Mawson Infrastructure Group
0.0$0.89+6.7%$471.73 millionN/A0.00Upcoming Earnings
BMEA
Biomea Fusion
1.7$16.75+5.0%$457.70 millionN/A0.00Analyst Report
Analyst Revision
News Coverage
Gap Up
VECT
VectivBio
1.6$12.79+0.8%$431.65 millionN/A0.00Quiet Period Expiration
SGTX
Sigilon Therapeutics
1.4$13.25+6.0%$417.77 millionN/A0.00Earnings Announcement
Analyst Revision
News Coverage
Angion Biomedica logo
ANGN
Angion Biomedica
1.6$14.24+1.7%$412.78 millionN/A0.00Gap Down
Landos Biopharma logo
LABP
Landos Biopharma
1.5$11.15+8.5%$409.20 millionN/A0.00
RAIN
Rain Therapeutics
1.3$15.00+0.5%$391.61 millionN/A0.00
NexImmune logo
NEXI
NexImmune
2.0$17.15+7.7%$390.30 millionN/A0.00Gap Down
Terns Pharmaceuticals logo
TERN
Terns Pharmaceuticals
1.7$15.75+3.7%$380.90 millionN/A0.00
Gemini Therapeutics logo
GMTX
Gemini Therapeutics
1.7$9.39+8.2%$370.65 millionN/A0.00News Coverage
Gap Up
PRTG
Portage Biotech
0.0$28.65+2.1%$338.81 millionN/A0.00
HOWL
Werewolf Therapeutics
0.3$11.51+0.8%$319.45 millionN/A0.00Gap Up
Sensei Biotherapeutics logo
SNSE
Sensei Biotherapeutics
2.0$9.65+5.7%$312.00 millionN/A0.00Earnings Announcement
Analyst Revision
News Coverage
IMPL
Impel NeuroPharma
0.3$13.84+0.8%$270.84 millionN/A0.00
Kaleido Biosciences logo
KLDO
Kaleido Biosciences
1.5$6.46+9.9%$247.46 millionN/A-2.55
Unity Biotechnology logo
UBX
Unity Biotechnology
1.3$4.32+1.4%$233.40 millionN/A-2.30Earnings Announcement
VINC
Vincerx Pharma
1.0$16.34+1.0%$228.50 millionN/A0.00
Annovis Bio logo
ANVS
Annovis Bio
1.7$24.00+3.0%$161.73 millionN/A0.00Upcoming Earnings
Analyst Report
News Coverage
Gap Up
Decibel Therapeutics logo
DBTX
Decibel Therapeutics
2.1$7.05+9.4%$159.12 millionN/A0.00Earnings Announcement
Analyst Downgrade
News Coverage
Gap Up
LBPH
Longboard Pharmaceuticals
1.9$8.58+2.1%$148.19 millionN/A0.00
ImmunoPrecise Antibodies logo
IPA
ImmunoPrecise Antibodies
0.0$7.85+4.5%$143.77 millionN/A0.00Gap Up
GANX
Gain Therapeutics
1.7$9.79+8.1%$106.89 millionN/A0.00Gap Up
EVAX
Evaxion Biotech A/S
1.7$5.30+5.7%$101.76 millionN/A0.00News Coverage
Gap Up
Trading Halted
LGVN
Longeveron
0.0$5.20+1.9%$98.58 millionN/A0.00News Coverage
VRDN
Viridian Therapeutics
1.7$17.52+3.8%$68.47 millionN/A0.00News Coverage
Gap Up
UPC
Universe Pharmaceuticals
0.0$3.20+3.4%$67.21 millionN/A0.00Gap Up
Inhibikase Therapeutics logo
IKT
Inhibikase Therapeutics
1.0$4.60+6.5%$49.29 millionN/A0.00Gap Down
CUBT
Curative Biotechnology
0.0$0.11+8.7%$44.64 millionN/A0.00Gap Up
Viracta Therapeutics logo
VIRX
Viracta Therapeutics
1.5$7.67+0.1%$39.63 millionN/A0.00Analyst Downgrade
Gap Up
VIRI
Virios Therapeutics
1.3$4.71+2.1%$39.23 millionN/A0.00News Coverage
CMMB
Chemomab Therapeutics
1.7$17.41+4.7%$38.77 millionN/A0.00Earnings Announcement
Analyst Report
News Coverage
Gap Up
NLS Pharmaceutics logo
NLSP
NLS Pharmaceutics
1.7$3.43+6.7%$37.69 millionN/A0.00Gap Up
VYNT
Vyant Bio
0.0$3.35+14.0%$31.70 millionN/A0.00Upcoming Earnings
News Coverage
MYMD
MyMD Pharmaceuticals
0.0$3.63+0.3%$30.31 millionN/A0.00Upcoming Earnings
VLON
Vallon Pharmaceuticals
0.0$3.71+1.1%$25.27 millionN/A0.00News Coverage
VRPX
Virpax Pharmaceuticals
0.3$3.85+2.6%$19.04 millionN/A0.00Gap Down
BCTX
BriaCell Therapeutics
0.0$3.18+3.1%$17.91 millionN/A0.00Gap Up
PALI
Palisade Bio
0.0$3.95+16.5%$13.26 millionN/A0.00Upcoming Earnings
Gap Down
ADiTx Therapeutics logo
ADTX
ADiTx Therapeutics
1.0$2.32+0.4%$0.00N/A0.00Earnings Announcement
Apotheca Biosciences logo
CBDC
Apotheca Biosciences
0.4$0.06+0.0%$0.00N/A0.00Gap Down
This page was last updated on 5/14/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.